FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990484619> ?p ?o ?g. }

• W1990484619 endingPage "e14501" @default.
• W1990484619 startingPage "e14501" @default.
• W1990484619 abstract "Background New antimalarials are needed for P. vivax and P. falciparum malaria. This study compared the efficacy and safety of pyronaridine-artesunate with that of chloroquine for the treatment of uncomplicated P. vivax malaria. Methods and Findings This phase III randomized, double-blind, non-inferiority trial included five centers across Cambodia, Thailand, India, and Indonesia. In a double-dummy design, patients (aged >3–≤60 years) with microscopically confirmed P. vivax mono-infection were randomized (1∶1) to receive pyronaridine-artesunate (target dose 7.2∶2.4 mg/kg to 13.8∶4.6 mg/kg) or chloroquine (standard dose) once daily for three days. Each treatment group included 228 randomized patients. Outcomes for the primary endpoint, Day-14 cure rate in the per-protocol population, were 99.5%, (217/218; 95%CI 97.5, 100) with pyronaridine-artesunate and 100% (209/209; 95%CI 98.3, 100) with chloroquine. Pyronaridine was non-inferior to chloroquine: treatment difference −0.5% (95%CI −2.6, 1.4), i.e., the lower limit of the 2-sided 95%CI for the treatment difference was greater than −10%. Pyronaridine-artesunate cure rates were non-inferior to chloroquine for Days 21, 28, 35 and 42. Parasite clearance time was shorter with pyronaridine-artesunate (median 23.0 h) versus chloroquine (32.0 h; p<0.0001), as was fever clearance time (median 15.9 h and 23.8 h, respectively; p = 0.0017). Kaplan-Meier estimates of post-baseline P. falciparum infection incidence until Day 42 were 2.5% with pyronaridine-artesunate, 6.1% with chloroquine (p = 0.048, log-rank test). Post-baseline P. vivax or P. falciparum infection incidence until Day 42 was 6.8% and 12.4%, respectively (p = 0.022, log rank test). There were no deaths. Adverse events occurred in 92/228 (40.4%) patients with pyronaridine-artesunate and 72/228 (31.6%) with chloroquine. Mild and transient increases in hepatic enzymes were observed for pyronaridine-artesunate. Conclusion Pyronaridine-artesunate efficacy in acute uncomplicated P. vivax malaria was at least that of chloroquine. As pyronaridine-artesunate is also efficacious against P. falciparum malaria, this combination has potential utility as a global antimalarial drug. Trial registration Clinicaltrials.gov NCT00440999" @default.
• W1990484619 created "2016-06-24" @default.
• W1990484619 creator A5010760440 @default.
• W1990484619 creator A5012856970 @default.
• W1990484619 creator A5014977844 @default.
• W1990484619 creator A5020224633 @default.
• W1990484619 creator A5023145210 @default.
• W1990484619 creator A5026917090 @default.
• W1990484619 creator A5033676700 @default.
• W1990484619 creator A5034311856 @default.
• W1990484619 creator A5043866303 @default.
• W1990484619 creator A5053573201 @default.
• W1990484619 creator A5054484476 @default.
• W1990484619 creator A5068237755 @default.
• W1990484619 creator A5083932794 @default.
• W1990484619 date "2011-01-18" @default.
• W1990484619 modified "2023-10-14" @default.
• W1990484619 title "Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial" @default.
• W1990484619 cites W1951642591 @default.
• W1990484619 cites W1973393206 @default.
• W1990484619 cites W1991072114 @default.
• W1990484619 cites W1993147489 @default.
• W1990484619 cites W1995608107 @default.
• W1990484619 cites W1997664087 @default.
• W1990484619 cites W1997792508 @default.
• W1990484619 cites W2006328367 @default.
• W1990484619 cites W2012849406 @default.
• W1990484619 cites W2036537237 @default.
• W1990484619 cites W2048350387 @default.
• W1990484619 cites W2055437693 @default.
• W1990484619 cites W2070076574 @default.
• W1990484619 cites W2074438244 @default.
• W1990484619 cites W2082742535 @default.
• W1990484619 cites W2085154693 @default.
• W1990484619 cites W2092290756 @default.
• W1990484619 cites W2097432479 @default.
• W1990484619 cites W2105765899 @default.
• W1990484619 cites W2111539591 @default.
• W1990484619 cites W2113915901 @default.
• W1990484619 cites W2117064443 @default.
• W1990484619 cites W2119130553 @default.
• W1990484619 cites W2132107151 @default.
• W1990484619 cites W2133465110 @default.
• W1990484619 cites W2135011211 @default.
• W1990484619 cites W2135837557 @default.
• W1990484619 cites W2143813429 @default.
• W1990484619 cites W2143838330 @default.
• W1990484619 cites W2148921550 @default.
• W1990484619 cites W2151004635 @default.
• W1990484619 cites W2152507925 @default.
• W1990484619 cites W2157912408 @default.
• W1990484619 cites W2158780951 @default.
• W1990484619 cites W2217354070 @default.
• W1990484619 cites W2397256145 @default.
• W1990484619 cites W283250592 @default.
• W1990484619 doi "https://doi.org/10.1371/journal.pone.0014501" @default.
• W1990484619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3022577" @default.
• W1990484619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21267072" @default.
• W1990484619 hasPublicationYear "2011" @default.
• W1990484619 type Work @default.
• W1990484619 sameAs 1990484619 @default.
• W1990484619 citedByCount "79" @default.
• W1990484619 countsByYear W19904846192012 @default.
• W1990484619 countsByYear W19904846192013 @default.
• W1990484619 countsByYear W19904846192014 @default.
• W1990484619 countsByYear W19904846192015 @default.
• W1990484619 countsByYear W19904846192016 @default.
• W1990484619 countsByYear W19904846192017 @default.
• W1990484619 countsByYear W19904846192018 @default.
• W1990484619 countsByYear W19904846192019 @default.
• W1990484619 countsByYear W19904846192020 @default.
• W1990484619 countsByYear W19904846192021 @default.
• W1990484619 countsByYear W19904846192022 @default.
• W1990484619 countsByYear W19904846192023 @default.
• W1990484619 crossrefType "journal-article" @default.
• W1990484619 hasAuthorship W1990484619A5010760440 @default.
• W1990484619 hasAuthorship W1990484619A5012856970 @default.
• W1990484619 hasAuthorship W1990484619A5014977844 @default.
• W1990484619 hasAuthorship W1990484619A5020224633 @default.
• W1990484619 hasAuthorship W1990484619A5023145210 @default.
• W1990484619 hasAuthorship W1990484619A5026917090 @default.
• W1990484619 hasAuthorship W1990484619A5033676700 @default.
• W1990484619 hasAuthorship W1990484619A5034311856 @default.
• W1990484619 hasAuthorship W1990484619A5043866303 @default.
• W1990484619 hasAuthorship W1990484619A5053573201 @default.
• W1990484619 hasAuthorship W1990484619A5054484476 @default.
• W1990484619 hasAuthorship W1990484619A5068237755 @default.
• W1990484619 hasAuthorship W1990484619A5083932794 @default.
• W1990484619 hasBestOaLocation W19904846191 @default.
• W1990484619 hasConcept C126322002 @default.
• W1990484619 hasConcept C168563851 @default.
• W1990484619 hasConcept C203014093 @default.
• W1990484619 hasConcept C2776120307 @default.
• W1990484619 hasConcept C2777425658 @default.
• W1990484619 hasConcept C2778048844 @default.
• W1990484619 hasConcept C2778059366 @default.
• W1990484619 hasConcept C2778371730 @default.
• W1990484619 hasConcept C2779997623 @default.

• next